Navigation Links
Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
Date:10/10/2007

y fail to obtain regulatory approval of NKTR- 102, (iv) potential competition from approved drugs or drugs under development that may be safe and effective for the same indication as that targeted by NKTR-102, and (v) the company's patent applications for NKTR-102 may fail to issue; patents that have issued may not be enforceable; or unanticipated intellectual property licenses from third parties may be required in the future. Other important risks and uncertainties are detailed in the company's reports and other filings with the SEC including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events, or otherwise. No information regarding or presented at the scientific meetings referred to above (or contained at the Internet links provided) is intended to be incorporated by reference in this press release.

Contacts:

Tim Warner (650) 283-4915 or twarner@nektar.com

Stephan Herrera (415) 488-7699 or sherrera@nektar.com

Jennifer Ruddock (650) 631-4954 or jruddock@nektar.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
3. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
4. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
7. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:7/10/2014)... July 10, 2014   LabStyle Innovations Corp ... today announced the appointment of Professor Richard ... its Board of Directors. Prof. Stone ... experience to LabStyle as an entrepreneur, venture capitalist ... corporate governance expert. He currently serves on the ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 ... nephrologists report awareness of the U.S. Food and Drug ... Pharma,s new phosphate binder Velphoro, which was approved by ... hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
(Date:7/11/2014)... York, New York (PRWEB) July 11, 2014 ... http://www.transvaginalmeshlawsuithelp.com/ ) , filed against Johnson & Johnson’s ... courts, Bernstein Liebhard LLP notes that the Texas ... investigating the company’s marketing of surgical mesh products ... urinary incontinence. According to a report from kens5.com, ...
(Date:7/11/2014)... Butler Mobility has recently updated the paint color choices ... Previously the two standard colors were beige and brown. ... as standard colors at no additional charge! These colors ... enhance the beauty of the stairway. Homeowners will find ... individual décor. , The new selection of standard colors is: ...
(Date:7/11/2014)... News) -- Reducing the number of deer in an ... and other tick-borne infections among people, new research indicates. ... manipulated to reduce human interactions with deer, infected nymphal ... researchers wrote. White-tailed deer are the primary host ... people. The study included nearly all the permanent ...
(Date:7/11/2014)... (HealthDay News) -- People with the lowest incomes may have ... disease (PAD), a new study suggests. People with PAD ... limbs, most often the legs. The condition causes leg pain ... throughout the body. People with PAD have a higher risk ... nearly 6,800 people with PAD who took part in the ...
(Date:7/11/2014)... Dennis Thompson HealthDay Reporter ... Mississippi girl born with HIV who was thought to be ... new tests showing detectable levels of the AIDS-causing virus in ... girl, now nearly 4 years old, had remained virus-free even ... months old. Doctors had hoped her remission would open the ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3
... SAN FRANCISCO, Sept. 15 The Gladstone ... Quantitative Biomedical Research (QB3) at the University of California, ... (CDD) are pleased to announce the prestigious speakers and ... Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian ...
... (Sept. 15, 2009) A research project looking for ... of improving the bone health of cancer patients undergoing radiation ... microgravity environment of space causes bone loss in astronauts, but ... radiation on bones. Dr. Ted Bateman leads a project funded ...
... , , , ... the innovative healthcare company supporting the nation,s foremost cancer treatment and ... 2009 InformationWeek 500, an annual listing of the nation,s most innovative ... establishment of an enterprise-wide CRM platform. , , ...
... could improve long-term health, researchers say , TUESDAY, Sept. ... a greater risk of becoming obese in adulthood, new ... online Sept. 11 in the journal BMC Medicine ... Psychiatry Center at the Institute of Psychiatry at King,s ...
... , BURBANK, Calif., Sept. 15 ... Los Angeles and the Childrens Hospital Los Angeles Medical Group has ... treatment for a group that nationwide falls in a gap between ... The Adolescent & Young Adult Cancer Program ...
... Industries have ... million since ... and campaign ... and HMO political contributions and lobbying expenses found the industries spent $126,430,438 over the first half of 2009 and ...
Cached Medicine News:Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 2Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 3Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 4Health News:Space-related radiation research could help reduce fractures in cancer survivors 2Health News:Space-related radiation research could help reduce fractures in cancer survivors 3Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 2Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 3Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 4Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 5Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 6Health News:Anxious Kids at Risk for Obesity in Adulthood 2Health News:Young Adults with Cancer Focus of Program Developed by Providence Saint Joseph Medical Center and Childrens Hospital Los Angeles 2Health News:Young Adults with Cancer Focus of Program Developed by Providence Saint Joseph Medical Center and Childrens Hospital Los Angeles 3Health News:Insurance and HMO Industries Spend Nearly $700,000 Per Day to Kill Health Care Reform Measures 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: